Nigerian-German Chemicals Valuation
Is NIG-GERMAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NIG-GERMAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NIG-GERMAN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NIG-GERMAN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NIG-GERMAN?
Other financial metrics that can be useful for relative valuation.
What is NIG-GERMAN's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₦556.71m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does NIG-GERMAN's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.6x | ||
NEIMETH Neimeth International Pharmaceuticals | 5.2x | n/a | ₦7.7b |
MAYBAKER May & Baker Nigeria | 1.2x | n/a | ₦10.4b |
GLAXOSMITH GlaxoSmithKline Consumer Nigeria | 2.2x | n/a | ₦20.3b |
FIDSON Fidson Healthcare | 1.9x | n/a | ₦36.5b |
NIG-GERMAN Nigerian-German Chemicals | n/a | n/a | ₦556.7m |
Price-To-Book vs Peers: Insufficient data to calculate NIG-GERMAN's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Earnings Ratio vs Industry
How does NIG-GERMAN's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?
Price-To-Book vs Industry: Insufficient data to calculate NIG-GERMAN's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is NIG-GERMAN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | n/a |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate NIG-GERMAN's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.